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Shared medical appointments improve
QOL in neuromuscular patients
A randomized controlled trial
ABSTRACT
Objective: To systematically study the effects of shared medical appointments (SMAs) compared
with individual appointments for patients with a chronic neuromuscular disorder and their
partners.
Methods: In this randomized controlled trial with a follow-up of 6 months, we included patients
with a chronic neuromuscular disorder and their partners. Participants were randomly allocated
to an SMA or an individual outpatient appointment. The primary outcome measure was patients’
health-related quality of life (QOL) (36-Item Short Form Health Survey). Secondary outcome
measures included self-efficacy, social support, patient and partner satisfaction with the appoint-
ment, and time available per patient.
Results: Two hundred seventy-two patients and 149 partners were included. Health-related QOL
showed greater improvement in patients who had attended an SMA (mean difference 2.8 points,
95% confidence interval 0.0–5.7, p 5 0.05). Secondary outcomes showed small improvements
in the control group for satisfaction with the appointment (p5 0.01). Neurologists spent less time
per patient during the SMAs: mean 16 minutes (range 11–30) vs 25 minutes (range 20–30) for
individual appointments.
Conclusions: This study provides evidence that SMAs can improve aspects of QOL of patients
with a chronic neuromuscular disorder. This could result in an alternative to individual appoint-
ments and improvements in both effectiveness and efficiency. Further research to optimize SMAs
and to identify critical success factors seems warranted. These data extend evidence on SMAs
for neurologic patients.
Classification of evidence: This study provides Class III evidence that for patients with chronic neu-
romuscular disorders, SMAs improve QOL as compared with individual medical appointments.
Neurology® 2014;83:240–246
GLOSSARY
CONSORT5Consolidated Standards of Reporting Trials; EQ-5D5 EuroQOL 5 dimensions questionnaire; HRQOL5 health-
related quality of life; INQoL 5 Individualized Neuromuscular Quality of Life Questionnaire; QOL 5 quality of life; QUOTE 5
QUality Of care Through the patient’s Eyes; RCT5 randomized controlled trial; SF-365 36-Item Short Form Health Survey;
SMA 5 shared medical appointment; VAS 5 visual analog scale.
Health care faces the challenge of finding an optimal balance between quality of care and time
available per patient, prompting hospitals and physicians to search for alternative care options.
Specifically for patients with a chronic neuromuscular disorder, it is difficult to fulfill their com-
plex needs during a conventional individual appointment. Moreover, in absence of cure, the
main treatment goals focus on optimizing quality of life (QOL) and improving self-
management. Accumulating evidence suggests an association between shared medical appoint-
ments (SMAs) and improvements in patient-reported outcome measures for various common,
mostly chronic, diseases.1–4 Feasibility of SMAs has recently been reported in Parkinson disease3;
however, the evidence for effectiveness of SMAs compared with individual appointments for
patients with Parkinson disease or other neurologic diseases has not been conclusive.
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During an SMA, also known as group visit,
a physician sees multiple patients simulta-
neously, combining individualized medical
patient care with peer support and self-
management education. This gives patients
and partners the opportunity to not only share
a health care professional’s time but also share
mutual experiences.5–7 In addition, the conti-
nuity and repetition offered during a series of
multiple SMAs, as described in most previous
randomized studies, may at least partly account
for the observed outcomes.8 A series of SMAs
is, however, not always feasible or desirable for
most groups of neurologic patients.
With the present randomized controlled
trial (RCT), we therefore wished to evaluate
whether even a single SMA would yield bene-
ficial effects on QOL relative to an individual
appointment for patients with chronic neuro-
muscular disorders and their partners.
METHODS Study design. Methods are described in accor-
dance with the CONSORT 2010 statement and have been reported
in detail elsewhere.9,10 In brief, we conducted an RCTwith a follow-
up of 6 months and randomized participants to either an SMA or an
individual appointment with one of the 2 participating neurologists
(B.v.E., G.D.) at the outpatient clinic of the neurology department
of the Radboud University Medical Centre.
The primary research question for this study was whether a
single SMA improves health-related QOL (HRQOL) for patients
with chronic neuromuscular disorders as compared with individ-
ual medical appointments.
The secondary research questions were whether a single SMA
improves individualized neuromuscular QOL, self-efficacy, social
support, and satisfaction with care for patients with chronic neu-
romuscular disorders, and QOL, self-efficacy, and satisfaction
with care for the patients’ partners.
This study provides Class III evidence that for patients with
chronic neuromuscular disorders, an SMA improves QOL com-
pared with an individual medical appointment.
Standard protocol approvals, registrations, and patient
consents. This trial was approved by the regional medical ethics
committee, and written informed consent was obtained from all
participants, including partners. The trial was registered with the
Dutch Trial Register, number NTR1412 (www.trialregister.nl).
Participants. Patients identified through CRAMP (Computer
Registry of All Myopathies and Polyneuropathies), the Dutch
neuromuscular database, were recruited between March 2009
and March 2011.11 Eligible patients were invited to participate
together with their partners. Patients were eligible if they were
diagnosed with one of the selected chronic neuromuscular disor-
ders (see table 1), were older than 18 years, currently in the care of
our department, and had not seen their neurologist 6 months
before study commencement. Exclusion criteria were severe hear-
ing problems or insufficient command of the Dutch language.10
Randomization. Concealed randomization (1:1) balanced by
diagnosis was performed using computer-generated randomization
software. In view of the nature of the intervention, physicians and
participants could not be blinded to group assignment. The
statistician who conducted the analyses was blinded to treatment
allocation.
Intervention. Patients and partners randomized to the SMA
group of the study were invited to attend an SMA of 1.5 to 2
hours in lieu of their annual appointment. During the SMA,
one of 2 neurologists (either B.v.E. or G.D.) saw 5 to 8 patients
with the same diagnosis and their partners simultaneously, ad-
dressing the same topics that are frequently covered during an
individual appointment. The neurologist was supported by a
group mentor who facilitated the group process by fostering inter-
action between patients and partners and by managing time. Both
neurologists and the group mentor had received training in con-
ducting SMAs before the study. For a more detailed description
of the content of the SMAs, see appendix e-1 on the Neurology®
Web site at Neurology.org. Patients (and their partners)
randomized to the control group were seen individually by one
of the neurologists during their regular annual 20- to 30-minute
appointment in which the customary topics were addressed. In
both conditions, patients were not necessarily seen by their
regular consulting physician. For both intervention groups, care
was tailored to the needs of the patients and their partners.
Prescriptions, referrals, and medical record-keeping were as usual.
Outcomes. The primary outcome measure was HRQOL as mea-
sured using the 36-Item Short Form Health Survey (SF-36).12 The
secondary outcome measures included the following: (1) HRQOL
as measured by the EuroQOL 5 dimensions questionnaire
(EQ-5D) generating 2 indices—the descriptive profile was used
to calculate a single summary EQ-5D index score and an overall
self-rated health status as measured by the visual analog scale
(VAS)13,14; (2) the Individualized Neuromuscular Quality of Life
Questionnaire (INQoL)15,16; (3) the Generalized Self-Efficacy Scale
by Schwarzer whereby the respondents rate the confidence they
have in being able to perform specific behaviours17; (4) the
emotional support subscale of the Dutch Social Support List–
Discrepancies Questionnaire18; (5) QUality Of care Through the
patient’s Eyes (QUOTE) inventory consisting of questions on
communication, treatment, symptoms, and medication19; (6)
satisfaction with the appointment, rated on a 5-point scale; and
(7) satisfaction with the marital relationship, rated on a 10-point
scale and a VAS.20
Potential differences in impact between the SMA and the
individual appointments on the patients’ partners were evaluated
by the following: (1) the EQ-5D; (2) the Generalized Self-
Efficacy Scale; (3) the QUOTE inventory; (4) satisfaction with
the appointment (5-point scale); (5) satisfaction with the marital
relationship (10-point scale and VAS); and (6) burden of care,
specifically, how many hours per week the respondent spends on
caring for and relieving the partner of household tasks.21
All outcome measures were obtained through standardized
self-reported questionnaires. Patients and partners received these
by mail at home 4 weeks before and 1, 12, and 24 weeks after the
intervention. Severity of neuromuscular disorders was clinician-
rated (B.v.E., G.D.) using the modified Rankin Scale.22,23
Because of the type of intervention, we did not expect to see a
change in incidence of adverse events, and thus information
about adverse events was not collected systematically.
Statistical analysis. A sample-size calculation showed that
92 patients per group were needed to demonstrate an
improvement of 5 points on the SF-36.12 Assuming an SD of
12, a power of 80%, a 2-sided a of 0.05, and considering loss to
follow-up, 135 patients had to be enrolled in both groups.
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Statistical analyses were performed using SPSS software (version
18; SPSS, Inc., Chicago, IL). Descriptive statistics were used to
present baseline characteristics. For the primary analyses, we used
a Toeplitz covariance model to conduct separate repeated-
measures analyses.24 We included time, treatment, and the
interaction between time and treatment as fixed factors in the
linear mixed model. In addition, we added the baseline values of
the dependent variables as possible significant covariates to the
model and corrected for variables that demonstrated an imbalance
at baseline.7 When the interaction factor did not show significant
results, it was discarded from the model. Residual plots from the
mixed models were examined to assess model assumptions. All
linear mixed-model analyses were performed on all participants,
including those with incomplete datasets. Two-tailed analyses
Table 1 Baseline participant characteristics for the 2 study groups
Variable
SMA Individual appointment
Patients
(n 5 123)
Partners
(n 5 66)
Patients
(n 5 112)
Partners
(n 5 58)
Age, y, mean (SD) 50 (13.5) 54 (2.9) 52 (13.3) 56 (11.6)
Men 63 (51.2) — 62 (55.4) —
Relationship 86 (70.5) — 79 (72.5) —
Diagnosis
Myotonic dystrophy type 1 45 (36.6) 25 (37.9) 30 (26.8) 12 (20.7)
Facioscapulohumeral muscular dystrophy 24 (19.5) 14 (21.2) 23 (20.5) 11 (19.0)
Nondystrophic myotonias: chloride and sodium channelopathies 9 (7.3) 4 (6.1) 12 (10.7) 6 (10.3)
Myositis: dermatomyositis and polymyositis 7 (5.7) 3 (4.5) 12 (10.7) 7 (12.1)
Polyneuropathy 14 (11.4) 6 (9.1) 15 (13.4) 6 (10.3)
Inclusion body myositis 4 (3.3) 3 (4.5) 5 (4.5) 4 (6.9)
Chronic progressive external ophthalmoplegia 4 (3.3) 1 (1.5) 1 (0.9) 1 (1.7)
McArdle disease 5 (4.1) 3 (4.5) 3 (2.7) 2 (3.4)
Oculopharyngeal muscular dystrophy 11 (8.9) 7 (10.6) 11 (9.8) 9 (15.5)
Modified Rankin Scale (higher scores indicate more severe
symptoms)
0 4 (3.4) — 8 (8.2) —
1 19 (16.0) — 13 (13.4) —
2 39 (32.8) — 35 (36.1) —
3 21 (17.6) — 14 (14.4) —
4 34 (28.6) — 27 (27.8) —
5 2 (1.7) — 0 (0) —
Level of education
Low 28 (23.1) 15 (25.4) 25 (22.9) 13 (26.0)
Medium 58 (47.9) 25 (42.4) 55 (50.5) 23 (46.0)
High 35 (28.9) 19 (32.2) 29 (26.6) 14 (28.0)
Employment status
Studying/in training 2 (1.7) 0 (0.0) 2 (1.9) 0 (0.0)
Paid work 42 (36.5) 35 (60.3) 33 (31.1) 22 (43.1)
Housework/volunteer work 8 (7.0) 4 (6.9) 7 (6.6) 7 (13.7)
Searching for a job 2 (1.7) 0 (0) 1 (0.9) 2 (3.9)
(Partially) medically retired 36 (31.3) 2 (3.4) 37 (34.9) 3 (5.9)
Retired 25 (21.7) 17 (29.3) 26 (24.5) 17 (33.3)
Attended SMA before 28 (23.0) 16 (27.1) 16 (14.5) 11 (21.6)
Membership of the Dutch patient association for muscle
diseases
71 (58.2) 18 (31.0) 51 (46.4) 9 (18.0)
Appointment with own neurologist 20 (16.3) 11 (16.7) 34 (30.6) 23 (39.7)
Abbreviation: SMA 5 shared medical appointment.
Data are n (%) unless stated otherwise.
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were performed with a p value of 0.05. Similar analyses were
conducted to determine differences in secondary outcome
measures.
RESULTS A total of 880 patients were assessed for eli-
gibility (see the figure [patient flowchart]), of whom
286 did not meet the inclusion criteria, leaving 594
eligible patients who were invited by telephone and
subsequent information letter to participate in the study
together with their partner, if relevant. Of these, 99
patients were not traceable, while 220 patients declined
to participate, of whom 17.7% refused participation in
an SMA, 29% reported practical barriers, 3.2% re-
ported too low energy levels, and 50% declined for
various other reasons. In total, 272 patients and 149
partners were included in the study, and 23 SMAs and
122 individual appointments were conducted.
Patients and partners in the 2 groups were similar
at baseline for most variables (see table 1). In the
SMA group, slightly more patients were diagnosed
with myotonic dystrophy type 1 and fewer patients
were seen by their own neurologist. These differences
were corrected for in the statistical analyses.
Modeled data (table 2) showed a beneficial effect
of SMAs on the primary outcome HRQOL as mea-
sured by 2 SF-36 subscales: for general health, the
mean difference between groups was 2.8 irrespective
of follow-up time (p 5 0.05); for social functioning,
an interaction was found between treatment and time
(p 5 0.03), indicating that SMAs and individual ap-
pointments had a different impact on this aspect of
the quality of the lives of the patients over time. The
other SF-36 subscales showed no significant trends.
Secondary outcomes for patients showed higher
values for QOL as measured by the INQoL fatigue
scale in the SMA group relative to the control group,
with different treatment effects across time points re-
sulting from the interaction between time and treat-
ment (p 5 0.03). Patient satisfaction with the
appointment was lower in the SMA group—QUOTE
scores were lower by 0.2 points and ratings on the
5-point scale by 0.4 points (p 5 0.01 and p 5
0.001, respectively). Perceived social support scores
were 1.1 points higher in the individual appointment
group (p5 0.004). The remaining secondary outcome
measures for patients showed no significant differences
between intervention groups (see table e-1).
The data for the patients’ partners showed no
between-group differences, except for satisfaction
with the appointment, in which the scores for the
SMA group were 0.3 points lower on the QUOTE
(p 5 0.01) and 0.4 points lower on the 5-point scale
(p 5 0.001) (see table e-2).
The neurologists spent less time per patient during
the SMAs, which lasted a mean of 16 minutes (range
11–30), compared with the individual appointments,
which averaged 25 minutes (range 20–30). In less
than 8% of the patients, individual attention was
needed after the SMA. This did not significantly
influence the total time spent per patient in the inter-
vention group.
DISCUSSION The main finding of this RCT is that a
single SMA resulted in a modest beneficial effect on
self-reported HRQOL (SF-36) compared with
individual appointments in patients with chronic
neuromuscular disorders, even though on average
considerably less time was spent per patient by the
neurologist during the SMAs. Secondary outcome
measures confirmed improvement of HRQOL on
a disease-specific scale (INQoL), although patient
and partner satisfaction with the appointment was
slightly lower in the SMA group. Based on these
Figure Patient flowchart: CRAMP
CRAMP 5 Computer Registry of All Myopathies and Polyneuropathies.
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results, we posit that even a single SMA has the
potential to improve both effectiveness and
efficiency of the care for patients with chronic
neuromuscular disorders, offering a viable
alternative to individual outpatient appointments.
Further research to optimize SMAs and to identify
critical success factors seems warranted before SMAs
can be more widely implemented in this and other
groups of neurologic patients. These data extend
evidence on SMAs for neurologic patients.
The main difference with earlier randomized SMA
studies is that we compared single SMAs with single
individual appointments, whereas all previous studies
except one evaluated a series of SMAs, in which it was
consistently suggested that effectiveness was related to
the number of SMAs patients attended.1,2,5,7,25,26
However, our study shows that even a single SMA
is able to improve aspects of HRQOL. The one study
that also evaluated a single SMA found no such ben-
efits.27 This difference in results may be attributable
to the fact that communication was more unidirec-
tional in the study by Abram et al., but for our SMAs,
we adopted a patient-driven agenda and actively
encouraged patients and their partners to share their
experiences. It is likely that the sharing and learning
from the experiences of fellow patients and peer sup-
port account for the effectiveness of the SMA model,
regardless of the effects of the repetitiveness and con-
tinuity of a succession of SMAs. In contrast to previ-
ous reports,4,5,28 we found that patients (and partners)
were slightly less satisfied with the SMA than those
receiving individual care. This result, too, might be
related to the fact that attending multiple successive
SMAs gives participants the opportunity to build a
relationship with peers and to acquaint themselves
with the new care model over time.
Finally, previous studies found the burden of care
for partners of chronically ill patients to be substantial
and recommended tailoring health care to the needs
of both patients and partners.20,21,29–33 To our knowl-
edge, ours is the first RCT to evaluate the differential
effects of an SMA and an individual appointment in
patients’ partners.8
Our study design was robust in that we were able
to include a sizeable sample of patients and their part-
ners in a randomized trial. Moreover, we prevented
bias caused by interphysician variation by having 2
neurologists deliver both the experimental interven-
tion and usual care. In addition, the wide range of
neuromuscular disorders is reflective of clinical prac-
tice and improves the generalizability of our results.
Also, refusal rates did not differ between intervention
groups. With this design, we were able to align the
intervention to usual care and to reliably compare
the effects of single SMAs with the effects of individ-
ual appointments.
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In addition to limitations such as limited generaliz-
ability because of a single-center design, possible influ-
ences of multiple outcome testing due to the subscales
of the SF-36, and the inability to apply participant
and physician blinding, 2 specific aspects of our study
warrant further discussion. First, among patients who
were invited to participate in the study, 25% refused
to be allocated to an SMA, suggesting that the partici-
pants who did agree to the randomization were proba-
bly motivated to meet with peers and share coping
strategies for a chronic condition. Second, although
the effect sizes of the improvements on our 2 HRQOL
primary outcome measures (SF-36) were similar to
those obtained in previous SMA studies,1,34 they did
not reach the minimally clinically important difference
of 5 points.12,35 The modesty of the effects may be
attributable to the progressive nature of chronic neuro-
muscular disorders.
Future research should focus on which determinants,
under which circumstances, account for the effectiveness
of SMAs. Among such determinants are the information
exchange among fellow patients, peer support, and the
sharing of experiences as well as the increased time to
inform patients and attend to psychosocial aspects.
Another research question meriting consideration is
the effect SMAs have on physicians and nurses regarding
job satisfaction. Finally, weighing the costs and effects of
our SMA intervention completely will require further
empirical data on the use of care resources.
An important implication of our study is that we
showed a wider applicability of the SMAmodel patients
whose intervals between successive appointments to the
clinic may be lengthy. This supports applicability to
other neurologic diseases provided that possibilities to
improve patient satisfaction are further explored.
Although modestly, the single SMA in this study
improved HRQOL, thus potentially offering patients
with chronic neuromuscular disorders and their part-
ners, as well as consulting neurologists, an alternative
care option; albeit, further refinements are needed
before SMAs can be more widely implemented in this
and other groups of neurologic patients.
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